Sildenafil Pill Images
For current labeling information, please visit endstream endobj 415 0 obj <> endobj 419 0 obj <> endobj 414 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 361 0 obj <> endobj 356 0 obj <>stream q 1 0 0 1 -8.856689 -1.917297 cm 0 0 612 792 re W n 1 0 0 1 8.856689 1.917297 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.1433 47.5827 Tm ( )Tj 19.25 -0.005 Td (3)Tj /TT1 1 Tf 0.0001 Tc -0.0001 Tw -19.25 54.925 Td (Absorption and Distribution:)Tj /TT0 1 Tf 0.0004 Tc -0.0004 Tw 12.51 0 Td [( VIAGRA is rapidly absorbed. Maxim)8.2 (um)8.2 ( observed plasm)8.2 (a)-0.8 ( )]TJ 0.0007 Tc -0.0007 Tw -12.51 -1.165 Td [(concentrations are reached within 30 to 120 m)8.5 (i)-1.5 (nutes \(m)8.5 (edian 60 m)8.5 (i)-1.5 (nutes\) of oral dosing in the )]TJ 0.0005 Tc -0.0005 Tw 0 -1.165 TD [(fasted state. W)9.3 (h)0.5 (en VIAGRA is taken with a high fat m)8.3 (eal, the rate of absorption is reduced, with )]TJ 0.0008 Tc -0.0008 Tw T* [(a m)8.6 (ean delay in T)]TJ -0.0184 Tc 0 Tw 7.98 0 0 7.98 149.1233 663.1827 Tm [(ma)-18.2 (x)]TJ 0.0005 Tc -0.0005 Tw 12 0 0 12 162.7433 664.6827 Tm [( of 60 m)8.3 (i)-1.7 (nutes and a m)8.3 (ean reduction in C)]TJ -0.0184 Tc 0 Tw 7.98 0 0 7.98 361.0433 663.1827 Tm [(ma)-18.2 (x)]TJ 0.0005 Tc -0.0005 Tw 12 0 0 12 374.6633 664.6827 Tm [( of 29%. The m)8.3 (e)-0.7 (an steady state )]TJ 0.0008 Tc -0.0008 Tw -25.96 -1.165 Td [(volum)8.6 (e of distribution \(Vss\) for sildenafil is 105 L, indicating distributi\ on into the tissues. )]TJ 0.0009 Tc -0.0009 Tw T* [(Sildenafil and its m)8.7 (ajor circulating N-desm)8.7 (ethyl m)8.7 (etabolite are both approxim)8.7 (ately 96% bound )]TJ 0.0008 Tc -0.0008 Tw T* [(to plasm)8.6 (a proteins. Protein binding is i)]TJ 0.0007 Tc -0.0007 Tw 15.495 0 Td (ndependent of total drug concentrations. )Tj 0 Tc 0 Tw -15.495 -1.165 Td ( )Tj 0.0006 Tc -0.0006 Tw T* [(Based upon m)8.4 (easurem)8.4 (ents of sildenafil in sem)8.4 (e)-0.6 (n of healthy volunteers 90 m)8.4 (i)-1.6 (nutes after dosing, )]TJ T* [(less than 0.001% of the adm)8.5 (i)-1.5 (nistered dose m)8.5 (ay appear in the sem)8.5 (en of patients. )]TJ 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0005 Tc -0.0005 Tw 0 -1.18 TD (Metabolism and Excretion:)Tj /TT0 1 Tf 0.0007 Tc -0.0007 Tw 11.68 0 Td [( Sildenafil is cleared predom)8.5 (inantly by the CYP3A4 \(m)8.5 (ajor route\) )]TJ 0.0008 Tc -0.0008 Tw -11.68 -1.165 Td [(and CYP2C9 \(m)8.6 (inor route\) hepatic m)8.6 (i)-1.4 (crosom)8.6 (al isoenzym)8.6 (es. The m)8.6 (ajor circulating m)8.6 (etabolite )]TJ 0.0009 Tc -0.0009 Tw 0 -1.165 TD [(results f)3.9 (r)-1.1 (om)8.7 ( N-desm)8.7 (ethylation of)3.9 ( sildenaf)3.9 (il, and is itself)3.9 ( f)3.9 (u)0.9 (rther m)8.7 (etabolized. This m)8.7 (etabolite has )]TJ 0.001 Tc -0.001 Tw T* [(a PDE selectivity prof)4 (ile sim)8.8 (ilar to sildenaf)4 (il and an )]TJ /TT2 1 Tf 0.0012 Tc -0.0012 Tw 21.055 0 Td (in vitro)Tj /TT0 1 Tf 0.0004 Tc -0.0004 Tw [( potency for PDE5 approxim)8.2 (a)-0.8 (tely )]TJ 0.0007 Tc -0.0007 Tw -21.055 -1.165 Td [(50% sildenafil oral jelly 100mg of the parent drug. Plasm)8.5 (a concentrations of this m)8.5 (etabolite are approxim)8.5 (ately 40% of those )]TJ 0.0009 Tc -0.0009 Tw T* [(seen for sildenafil, so that the m)8.7 (etabolite acc)]TJ 0.0007 Tc -0.0007 Tw 17.855 0 Td [(ounts for about 20% of sildenafil\222s pharm)8.5 (acologic )]TJ 0.0001 Tc -0.0001 Tw -17.855 -1.165 Td (effects. )Tj 0 Tc 0 Tw T* ( )Tj 0.001 Tc -0.001 Tw T* [(After either oral or intravenous adm)8.8 (i)-1.2 (nistration, sildenafil is excreted as m)8.8 (etabolites )]TJ 0.0008 Tc -0.0008 Tw T* [(predom)8.6 (inantly in the feces \(approxim)8.6 (ately 80% of adm)8.6 (i)-1.4 (nistered oral dose\) and to a lesser extent )]TJ 0.0009 Tc -0.0009 Tw T* [(in the urine \(approxim)8.7 (ately 13% of the adm)8.7 (i)-1.3 (nistered oral dose\).
Society and culture
For current labeling information, please visit endstream endobj 415 0 obj <> endobj 419 0 obj <> endobj 414 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 361 0 obj <> endobj 356 0 obj <>stream q 1 0 0 1 -8.856689 -1.917297 cm 0 0 612 792 re W n 1 0 0 1 8.856689 1.917297 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.1433 47.5827 Tm ( )Tj 19.25 -0.005 Td (3)Tj /TT1 1 Tf 0.0001 Tc -0.0001 Tw -19.25 54.925 Td (Absorption and Distribution:)Tj /TT0 1 Tf 0.0004 Tc -0.0004 Tw 12.51 0 Td [( VIAGRA is rapidly absorbed. Maxim)8.2 (um)8.2 ( observed plasm)8.2 (a)-0.8 ( )]TJ 0.0007 Tc -0.0007 Tw -12.51 -1.165 Td [(concentrations are reached within 30 to 120 m)8.5 (i)-1.5 (nutes \(m)8.5 (edian 60 m)8.5 (i)-1.5 (nutes\) of oral dosing in the )]TJ 0.0005 Tc -0.0005 Tw 0 -1.165 TD [(fasted state. W)9.3 (h)0.5 (en VIAGRA is taken with a high fat m)8.3 (eal, the rate of absorption is reduced, with )]TJ 0.0008 Tc -0.0008 Tw T* [(a m)8.6 (ean delay in T)]TJ -0.0184 Tc 0 Tw 7.98 0 0 7.98 149.1233 663.1827 Tm [(ma)-18.2 (x)]TJ 0.0005 Tc -0.0005 Tw 12 0 0 12 162.7433 664.6827 Tm [( of 60 m)8.3 (i)-1.7 (nutes and a m)8.3 (ean reduction in C)]TJ -0.0184 Tc 0 Tw 7.98 0 0 7.98 361.0433 663.1827 Tm [(ma)-18.2 (x)]TJ 0.0005 Tc -0.0005 Tw 12 0 0 12 374.6633 664.6827 Tm [( of 29%. The m)8.3 (e)-0.7 (an steady state )]TJ 0.0008 Tc -0.0008 Tw -25.96 -1.165 Td [(volum)8.6 (e of distribution \(Vss\) for sildenafil is 105 L, indicating distributi\ on into the tissues.
How should I store sildenafil?
)]TJ 0.0009 Tc -0.0009 Tw T* [(Sildenafil and its m)8.7 (ajor circulating N-desm)8.7 (ethyl m)8.7 (etabolite are both approxim)8.7 (ately 96% bound )]TJ 0.0008 Tc -0.0008 Tw T* [(to plasm)8.6 (a proteins. Protein binding is i)]TJ 0.0007 Tc -0.0007 Tw 15.495 0 Td (ndependent of total drug concentrations. )Tj 0 Tc 0 Tw -15.495 -1.165 Td ( )Tj 0.0006 Tc -0.0006 Tw T* [(Based upon m)8.4 (easurem)8.4 (ents of sildenafil in sem)8.4 (e)-0.6 (n of healthy volunteers 90 m)8.4 (i)-1.6 (nutes after dosing, )]TJ T* [(less than 0.001% of the adm)8.5 (i)-1.5 (nistered dose m)8.5 (ay appear in the sem)8.5 (en of patients. )]TJ 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0005 Tc -0.0005 Tw 0 -1.18 TD (Metabolism and Excretion:)Tj /TT0 1 Tf 0.0007 Tc -0.0007 Tw 11.68 0 Td [( Sildenafil is cleared predom)8.5 (inantly by the CYP3A4 \(m)8.5 (ajor route\) )]TJ 0.0008 Tc -0.0008 Tw -11.68 -1.165 Td [(and CYP2C9 \(m)8.6 (inor route\) hepatic m)8.6 (i)-1.4 (crosom)8.6 (al isoenzym)8.6 (es. The m)8.6 (ajor circulating m)8.6 (etabolite )]TJ 0.0009 Tc -0.0009 Tw 0 -1.165 TD [(results f)3.9 (r)-1.1 (om)8.7 ( N-desm)8.7 (ethylation of)3.9 ( sildenaf)3.9 (il, and is itself)3.9 ( f)3.9 (u)0.9 (rther m)8.7 (etabolized.
Does sildenafil interact with foods or drinks?
This m)8.7 (etabolite has )]TJ 0.001 Tc -0.001 Tw T* [(a PDE selectivity prof)4 (ile sim)8.8 (ilar to sildenaf)4 (il and an )]TJ /TT2 1 Tf 0.0012 Tc -0.0012 Tw 21.055 0 Td (in vitro)Tj /TT0 1 Tf 0.0004 Tc -0.0004 Tw [( potency for PDE5 approxim)8.2 (a)-0.8 (tely )]TJ 0.0007 Tc -0.0007 Tw -21.055 -1.165 Td [(50% sildenafil oral jelly 100mg of the parent drug. Plasm)8.5 (a concentrations of this m)8.5 (etabolite are approxim)8.5 (ately 40% of those )]TJ 0.0009 Tc -0.0009 Tw T* [(seen for sildenafil, so that the m)8.7 (etabolite acc)]TJ 0.0007 Tc -0.0007 Tw 17.855 0 Td [(ounts for about 20% of sildenafil\222s pharm)8.5 (acologic )]TJ 0.0001 Tc -0.0001 Tw -17.855 -1.165 Td (effects. )Tj 0 Tc 0 Tw T* ( )Tj 0.001 Tc -0.001 Tw T* [(After either oral or intravenous adm)8.8 (i)-1.2 (nistration, sildenafil is excreted as m)8.8 (etabolites )]TJ 0.0008 Tc -0.0008 Tw T* [(predom)8.6 (inantly in the feces \(approxim)8.6 (ately 80% of adm)8.6 (i)-1.4 (nistered oral dose\) and to a lesser extent )]TJ 0.0009 Tc -0.0009 Tw T* [(in the urine \(approxim)8.7 (ately 13% of the adm)8.7 (i)-1.3 (nistered oral dose\). Sim)8.7 (ilar values for )]TJ T* [(pharm)8.7 (acokinetic param)8.7 (eters were seen in norm)8.7 (al volunteers and in the patient population, using )]TJ 0.0008 Tc -0.0008 Tw T* [(a population pharm)8.6 (acokinetic approach. )]TJ /TT1 1 Tf 0 Tc 0 Tw 0 sildenafil pricing -1.18 TD ( )Tj 0.0006 Tc -0.0006 Tw 0 -1.17 TD (Pharmacokinetics in Special Populations )Tj 0.0014 Tc 0 Tw T* (Geriatrics:)Tj /TT0 1 Tf 0.0008 Tc -0.0008 Tw ( Healthy elderly volunteers \(65 years or over\) had a reduced clearance\ of sildenafil, )Tj 0 -1.165 TD [(with free plasm)8.6 (a concentrations approxim)8.6 (ately 40% greater than those seen in healthy younger )]TJ T* (volunteers \(18-45 years\). Sim)8.7 (ilar values for )]TJ T* [(pharm)8.7 (acokinetic param)8.7 (eters were seen in norm)8.7 (al volunteers and in the patient population, using )]TJ 0.0008 Tc -0.0008 Tw T* [(a population pharm)8.6 (acokinetic approach.
- Sildenafil white is a common name for the generic version of Viagra.
- It is used to treat erectile dysfunction in men.
- Sildenafil white is known for its rapid onset of action.
- The medication works by enhancing blood flow to the penis.
- It is typically taken about 30 to 60 minutes before sexual activity.
- Sildenafil white is available in various doses, usually 25mg, 50mg, and 100mg.
- The drug should not be used with nitrate medications to avoid dangerous interactions.
- Common side effects include headache, flushing, and nasal congestion.
- It is important to follow dosage instructions provided by a healthcare provider.
- Sildenafil white can cause low blood pressure in some users.
- Store sildenafil white in a cool, dry place, away from direct sunlight.
)]TJ /TT1 1 Tf 0 Tc 0 Tw 0 sildenafil pricing -1.18 TD ( )Tj 0.0006 Tc -0.0006 Tw 0 -1.17 TD (Pharmacokinetics in Special Populations )Tj 0.0014 Tc 0 Tw T* (Geriatrics:)Tj /TT0 1 Tf 0.0008 Tc -0.0008 Tw ( Healthy elderly volunteers \(65 years or over\) had a reduced clearance\ of sildenafil, )Tj 0 -1.165 TD [(with free plasm)8.6 (a concentrations approxim)8.6 (ately 40% greater than those seen in healthy younger )]TJ T* (volunteers \(18-45 years\). )Tj 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0006 Tc -0.0006 Tw 0 -1.18 TD (Renal Insufficiency:)Tj /TT0 1 Tf 0.0008 Tc -0.0008 Tw 8.595 0 Td [( In volunteers with m)8.6 (ild \(CLcr=50-80 m)8.6 (L)1.6 (/m)8.6 (in\) and m)8.6 (oderate )]TJ 0.0007 Tc -0.0007 Tw -8.595 -1.165 Td [(\(CLcr=30-49 m)8.5 (L)1.5 (/m)8.5 (in\) renal im)8.5 (pairm)8.5 (ent, the pharm)8.5 (acokinetics of a single oral dose of VIAGRA )]TJ 0.0009 Tc -0.0009 Tw 0 -1.165 TD [(\(50 m)8.7 (g)0.9 (\) were not altered. In volunteers with severe \(CLcr=<30 m)8.7 (L)1.7 (/m)8.7 (in\) renal im)8.7 (pairm)8.7 (ent, )]TJ 0.0006 Tc -0.0006 Tw T* [(sildenafil clearance was reduced, resulting in approxim)8.4 (a)-0.6 (tely doubling of AUC and C)]TJ -0.0184 Tc 0 Tw 7.98 0 0 7.98 470.1233 243.1228 Tm [(ma)-18.2 (x)]TJ 0 Tc 12 0 0 12 483.7432 244.6228 Tm ( )Tj 0.0009 Tc -0.0009 Tw -35.05 -1.165 Td [(com)8.7 (p)0.9 (ared to age-m)8.7 (atched volunteers with no renal im)8.7 (pairm)8.7 (ent. )]TJ /CS0 cs 1 0 0 scn 0 Tc 0 Tw T* ( )Tj 0 g /TT1 1 Tf 0.001 Tc -0.001 Tw 0 -1.18 TD (Hepatic Insufficiency: )Tj /TT0 1 Tf 0.0007 Tc -0.0007 Tw 9.685 0 Td (In volunteers with hepatic cirrhosis \(Child-Pugh A and B\), sildenafil \ )Tj -9.685 -1.165 Td (clearance was reduced, resulting in increases in AUC \(84%\) and C)Tj -0.0184 Tc 0 Tw 7.98 0 0 7.98 383.8433 187.0227 Tm [(ma)-18.2 (x)]TJ 0.001 Tc -0.001 Tw 12 0 0 12 397.4633 188.5227 Tm [( \(47%\) com)8.8 (p)1 (ared to )]TJ 0.0009 Tc -0.0009 Tw -27.86 -1.165 Td [(age-m)8.7 (atched volunteers with no hepatic im)8.7 (pairm)8.7 (ent.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 50mg | 360 + 10 Pills | 225.33€ 214.60€ | |
| Viagra Generic | 200mg | 180 + 10 Pills | 277.56€ 264.34€ | |
| Viagra Generic | 150mg | 60 + 4 Pills | 111.25€ 105.95€ | |
| Viagra Generic | 150mg | 10 Pills | 36.73€ 34.98€ | |
| Kamagra Polo | 100mg | 32 Pills | 125.88€ 119.89€ | |
| Kamagra Soft Tabs | 100mg | 12 Pills | 57.55€ 54.81€ | |
| Viagra Generic | 200mg | 90 + 6 Pills | 170.79€ 162.66€ | |
| Kamagra Soft Tabs | 100mg | 84 + 4 Pills | 233.05€ 221.95€ | |
| Kamagra | 100mg | 180 + 6 Pills | 436.79€ 415.99€ | |
| Kamagra Polo | 100mg | 272 + 12 Pills | 622.94€ 593.28€ |
)]TJ 0 Tc 0 Tw 0 -1.165 TD ( )Tj 0.0009 Tc -0.0009 Tw T* [(Therefore, age >65, hepatic im)8.7 (pairm)8.7 (ent and severe renal im)8.7 (pairm)8.7 (ent are associated with )]TJ 0.0006 Tc -0.0006 Tw T* [(increased plasm)8.4 (a)-0.6 ( levels of sildenafil.
Chemical synthesis
Sildenafil preparation and administration
Warnings for people with certain health conditions
A starting oral dose of 25 m)8.4 (g)0.6 ( should be considered in )]TJ 0.0011 Tc -0.0011 Tw 0 -1.18 TD (those patients \(see )Tj /TT1 1 Tf -0.0009 Tc 0.0009 Tw 7.6 0 Td (DOSAGE AND ADMINISTRATION)Tj /TT0 1 Tf 0.001 Tc 0 Tw 15.98 0 Td (\). )Tj 0 Tc -23.58 -1.165 Td ( )Tj ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 358 0 obj <>>>/Resources 421 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA.
- The term 'sildenafil white' often refers to unbranded, generic pills.
- It may be available online through various pharmacies and vendors.
- Users should verify the legitimacy of sildenafil sources to avoid fake products.
- This medication is not suitable for individuals with certain heart conditions.
- Sildenafil white is sometimes used recreationally for its euphoric effects.
- It may interact with certain antibiotics and antifungals, altering effectiveness.
- Patients should inform their doctor of all medications before use.
- The medication is not an aphrodisiac; it only facilitates erectile response.
- Overuse or misuse of sildenafil white can lead to serious health risks.
- The recommended maximum frequency is once per day unless advised otherwise.
- Consultation with a healthcare professional is essential prior to use.
) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 359 0 obj <>>>/Resources 423 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 423 0 obj <> endobj 424 0 obj <> endobj 422 0 obj <>stream /This label may not be the latest approved by FDA.
| Condition | Risk | Recommendation |
|---|---|---|
| Nitrate Use | Severe hypotension | Avoid combination |
| Heart Disease | Increased risk of cardiac event | Consult physician |
| Liver or Kidney Impairment | Altered drug metabolism | Dose adjustment necessary |
| Retinitis Pigmentosa | Potential for increased visual side effects | Use with caution |
For current labeling information, please visit endstream endobj 421 0 obj <> endobj 425 0 obj <> endobj 420 0 obj <>stream /This label may not be the latest approved by FDA.
| Drug Type | Effect on Sildenafil White | Notes |
|---|---|---|
| Nitrates | Potentiate hypotensive effects | Contraindicated |
| CYP3A4 Inhibitors | Increase sildenafil levels, risk of side effects | Use lower dose if necessary |
| Alpha-blockers | Risk of hypotension | Monitor blood pressure |
| P450 Enzyme Inducers | Decrease effectiveness | Monitor and adjust dosage |
For current labeling information, please visit endstream endobj 357 0 obj <> endobj 352 0 obj <>stream q 1 0 0 1 -8.74585 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.74585 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.2541 47.6228 Tm ( )Tj 19.25 -0.005 Td (2)Tj 0.0007 Tc -19.25 54.94 Td (Studies )Tj /TT1 1 Tf 0.0012 Tc -0.0012 Tw 3.2 0 Td (in vitro)Tj /TT0 1 Tf 0.0006 Tc -0.0006 Tw [( have shown that sildenafil is selective for PDE5. Its effect is m)8.4 (o)0.6 (re potent on )]TJ 0.0002 Tc -0.0002 Tw -3.2 -1.165 Td (PDE5 than on other known phosphodiesterases \(10-fold for PDE6, >80-fold\ for PDE1, )Tj -0.0004 Tc 0.0004 Tw 0 -1.165 TD (>700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11\). Th\ e )Tj 0.0005 Tc -0.0005 Tw T* [(approxim)8.3 (a)-0.7 (tely 4,000-fold selectivity for PDE5 versus PDE3 is im)8.3 (portant because PDE3 is )]TJ 0.0009 Tc -0.0009 Tw T* (involved in control of cardiac contractility.
5.7 Priapism
Silden)Tj 0.0005 Tc -0.0005 Tw 20.01 0 Td (afil is only about 10-fold as potent for PDE5 )Tj 0.0006 Tc -0.0006 Tw -20.01 -1.165 Td [(com)8.4 (p)0.6 (ared to PDE6, an enzym)8.4 (e)-0.6 ( found in sildenafil 50g the retina which is involved in the phototransduction )]TJ 0.0009 Tc -0.0009 Tw T* [(pathway of the retina. This lower selectivity is thought to be the basis\ for abnorm)8.7 (alities related to )]TJ 0.0008 Tc -0.0008 Tw 0 -1.18 TD [(color vision observed with higher doses or plasm)8.6 (a levels \(see )]TJ /TT2 1 Tf 0.0004 Tc 0 Tw 24.81 0 Td (Pharmacodynamics)Tj /TT0 1 Tf 0.001 Tc (\).
4.1 Nitrates
)Tj 0 Tc 0 Tw T* ( )Tj /TT1 1 Tf 0.0006 Tc -0.0006 Tw 0 -1.18 TD (Renal Insufficiency:)Tj /TT0 1 Tf 0.0008 Tc -0.0008 Tw 8.595 0 Td [( In volunteers with m)8.6 (ild \(CLcr=50-80 m)8.6 (L)1.6 (/m)8.6 (in\) and m)8.6 (oderate )]TJ 0.0007 Tc -0.0007 Tw -8.595 -1.165 Td [(\(CLcr=30-49 m)8.5 (L)1.5 (/m)8.5 (in\) renal im)8.5 (pairm)8.5 (ent, the pharm)8.5 (acokinetics of a single oral dose of VIAGRA )]TJ 0.0009 Tc -0.0009 Tw 0 -1.165 TD [(\(50 m)8.7 (g)0.9 (\) were not altered. In volunteers with severe \(CLcr=<30 m)8.7 (L)1.7 (/m)8.7 (in\) renal im)8.7 (pairm)8.7 (ent, )]TJ 0.0006 Tc -0.0006 Tw T* [(sildenafil clearance was reduced, resulting in approxim)8.4 (a)-0.6 (tely doubling of AUC and C)]TJ -0.0184 Tc 0 Tw 7.98 0 0 7.98 470.1233 243.1228 Tm [(ma)-18.2 (x)]TJ 0 Tc 12 0 0 12 483.7432 244.6228 Tm ( )Tj 0.0009 Tc -0.0009 Tw -35.05 -1.165 Td [(com)8.7 (p)0.9 (ared to age-m)8.7 (atched volunteers with no renal im)8.7 (pairm)8.7 (ent. )]TJ /CS0 cs 1 0 0 scn 0 Tc 0 Tw T* ( )Tj 0 g /TT1 1 Tf 0.001 Tc -0.001 Tw 0 -1.18 TD (Hepatic Insufficiency: )Tj /TT0 1 Tf 0.0007 Tc -0.0007 Tw 9.685 0 Td (In volunteers with hepatic cirrhosis \(Child-Pugh A and B\), sildenafil \ )Tj -9.685 -1.165 Td (clearance was reduced, resulting in increases in AUC \(84%\) and C)Tj -0.0184 Tc 0 Tw 7.98 0 0 7.98 383.8433 187.0227 Tm [(ma)-18.2 (x)]TJ 0.001 Tc -0.001 Tw 12 0 0 12 397.4633 188.5227 Tm [( \(47%\) com)8.8 (p)1 (ared to )]TJ 0.0009 Tc -0.0009 Tw -27.86 -1.165 Td [(age-m)8.7 (atched volunteers with no hepatic im)8.7 (pairm)8.7 (ent. )]TJ 0 Tc 0 Tw 0 -1.165 TD ( )Tj 0.0009 Tc -0.0009 Tw T* [(Therefore, age >65, hepatic im)8.7 (pairm)8.7 (ent and severe renal im)8.7 (pairm)8.7 (ent are associated with )]TJ 0.0006 Tc -0.0006 Tw T* [(increased plasm)8.4 (a)-0.6 ( levels of sildenafil. A starting oral dose of 25 m)8.4 (g)0.6 ( should be considered in )]TJ 0.0011 Tc -0.0011 Tw 0 -1.18 TD (those patients \(see )Tj /TT1 1 Tf -0.0009 Tc 0.0009 Tw 7.6 0 Td (DOSAGE AND ADMINISTRATION)Tj /TT0 1 Tf 0.001 Tc 0 Tw 15.98 0 Td (\).
Red Viagra
)Tj 0 Tc -23.58 -1.165 Td ( )Tj ET /Artifact <>BDC Q q 1 0 0 1 120.6970062 785.2004395 cm /GS1 gs /Fm0 Do Q EMC /Artifact <>BDC q 1 0 0 1 612 773.2004395 cm /GS1 gs /Fm1 Do Q EMC endstream endobj 358 0 obj <>>>/Resources 421 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 65.791 -7.9 Td (This ) Tj 22.92 0 Td (label ) Tj 26.055 0 Td (may ) Tj 22.71 0 Td (not ) Tj 18.12 0 Td (be ) Tj 14.692 0 Td (the ) Tj 18.023 0 Td (latest ) Tj 29.595 0 Td (approved ) Tj 48.974 0 Td (by ) Tj 14.17 0 Td (FDA. ) Tj -281.05 -12 Td (For ) Tj 18.96 0 Td (current ) Tj 38.765 0 Td (labeling ) Tj 41.055 0 Td (information, ) Tj 61.25 0 Td (please ) Tj 34.707 0 Td (visit ) Tj 22.299 0 Td ( Tj ET endstream endobj 359 0 obj <>>>/Resources 423 0 R/Subtype/Form>>stream 0 g 0 G 0 i 0 J []0 d 0 j 1 w 10 M 0 Tc 0 Tw 100 Tz 0 TL 0 Tr 0 Ts BT /ArialRoundedMTBold 10 Tf 0 0 1 rg 0 -7.9 Td ( ) Tj ET endstream endobj 423 0 obj <> endobj 424 0 obj <> endobj 422 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 421 0 obj <> endobj 425 0 obj <> endobj 420 0 obj <>stream /This label may not be the latest approved by FDA. For current labeling information, please visit endstream endobj 357 0 obj <> endobj 352 0 obj <>stream q 1 0 0 1 -8.74585 -1.877228 cm 0 0 612 792 re W n 1 0 0 1 8.74585 1.877228 cm BT /GS0 gs /TT0 1 Tf 12 0 0 12 63.2541 47.6228 Tm ( )Tj 19.25 -0.005 Td (2)Tj 0.0007 Tc -19.25 54.94 Td (Studies )Tj /TT1 1 Tf 0.0012 Tc -0.0012 Tw 3.2 0 Td (in vitro)Tj /TT0 1 Tf 0.0006 Tc -0.0006 Tw [( have shown that sildenafil is selective for PDE5. Its effect is m)8.4 (o)0.6 (re potent on )]TJ 0.0002 Tc -0.0002 Tw -3.2 -1.165 Td (PDE5 than on other known phosphodiesterases \(10-fold for PDE6, >80-fold\ for PDE1, )Tj -0.0004 Tc 0.0004 Tw 0 -1.165 TD (>700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11\).
Related treatment guides
Th\ e )Tj 0.0005 Tc -0.0005 Tw T* [(approxim)8.3 (a)-0.7 (tely 4,000-fold selectivity for PDE5 versus PDE3 is im)8.3 (portant because PDE3 is )]TJ 0.0009 Tc -0.0009 Tw T* (involved in control of cardiac contractility. Silden)Tj 0.0005 Tc -0.0005 Tw 20.01 0 Td (afil is only about 10-fold as potent for PDE5 )Tj 0.0006 Tc -0.0006 Tw -20.01 -1.165 Td [(com)8.4 (p)0.6 (ared to PDE6, an enzym)8.4 (e)-0.6 ( found in sildenafil 50g the retina which is involved in the phototransduction )]TJ 0.0009 Tc -0.0009 Tw T* [(pathway of the retina. This lower selectivity is thought to be the basis\ for abnorm)8.7 (alities related to )]TJ 0.0008 Tc -0.0008 Tw 0 -1.18 TD [(color vision observed with higher doses or plasm)8.6 (a levels \(see )]TJ /TT2 1 Tf 0.0004 Tc 0 Tw 24.81 0 Td (Pharmacodynamics)Tj /TT0 1 Tf 0.001 Tc (\). )Tj 0 Tc -24.81 -1.165 Td ( )Tj 0.0005 Tc -0.0005 Tw 0 -1.165 TD [(In addition to hum)8.3 (an corpus cavernosum)8.3 ( sm)8.3 (ooth m)8.3 (u)0.5 (scle, PDE5 is also found in lower )]TJ 0.001 Tc -0.001 Tw T* (concentrations in other tissues including platel)Tj 0.0008 Tc -0.0008 Tw [(ets, vascular and visceral sm)8.6 (ooth m)8.6 (u)0.8 (scle, and )]TJ 0.0007 Tc -0.0007 Tw T* [(skeletal m)8.5 (u)0.7 (scle. The inhibition of PDE5 in these tissues by sildenafil m)8.5 (ay be the basis for the )]TJ 0.0009 Tc -0.0009 Tw T* (enhanced platelet antiaggregatory activity of nitric oxide observed )Tj /TT1 1 Tf 0.0012 Tc -0.0012 Tw 26.825 0 Td (in vitro)Tj /TT0 1 Tf 0.0005 Tc -0.0005 Tw (, an inhibition of )Tj 0.0009 Tc -0.0009 Tw -26.825 -1.165 Td [(platelet throm)8.7 (bus form)8.7 (ation )]TJ /TT1 1 Tf 0.001 Tc -0.001 Tw 11.42 0 Td (in vivo )Tj /TT0 1 Tf (and peripheral arterial-venous dilatation )Tj /TT1 1 Tf 19.265 0 Td (in vivo)Tj /TT0 1 Tf 0 Tc 0 Tw (. )Tj 0 Tc -24.81 -1.165 Td ( )Tj 0.0005 Tc -0.0005 Tw 0 -1.165 TD [(In addition to hum)8.3 (an corpus cavernosum)8.3 ( sm)8.3 (ooth m)8.3 (u)0.5 (scle, PDE5 is also found in lower )]TJ 0.001 Tc -0.001 Tw T* (concentrations in other tissues including platel)Tj 0.0008 Tc -0.0008 Tw [(ets, vascular and visceral sm)8.6 (ooth m)8.6 (u)0.8 (scle, and )]TJ 0.0007 Tc -0.0007 Tw T* [(skeletal m)8.5 (u)0.7 (scle.
What does Sildenafil Citrate look like?
Super Kamagra
How is sildenafil supplied (dosage forms)?
The inhibition of PDE5 in these tissues by sildenafil m)8.5 (ay be the basis for the )]TJ 0.0009 Tc -0.0009 Tw T* (enhanced platelet antiaggregatory activity of nitric oxide observed )Tj /TT1 1 Tf 0.0012 Tc -0.0012 Tw 26.825 0 Td (in vitro)Tj /TT0 1 Tf 0.0005 Tc -0.0005 Tw (, an inhibition of )Tj 0.0009 Tc -0.0009 Tw -26.825 -1.165 Td [(platelet throm)8.7 (bus form)8.7 (ation )]TJ /TT1 1 Tf 0.001 Tc -0.001 Tw 11.42 0 Td (in vivo )Tj /TT0 1 Tf (and peripheral arterial-venous dilatation )Tj /TT1 1 Tf 19.265 0 Td (in vivo)Tj /TT0 1 Tf 0 Tc 0 Tw (.
